Nalaganje...
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with oestrogen-receptor-positive (ER+), HER2-negative breast cancer. Here, we descr...
Shranjeno v:
| izdano v: | NPJ Breast Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7881187/ https://ncbi.nlm.nih.gov/pubmed/33579961 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00216-w |
| Oznake: |
Označite
Brez oznak, prvi označite!
|